GSK5926371 / Chimagen Biosci, Zhejiang Hisun, GSK - LARVOL DELTA

Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: BioRay Pharmaceutical Co., Ltd. | N=209 ➔ 4 | Trial completion date: Apr 2030 ➔ Nov 2024 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2030 ➔ Aug 2024; sponsor's Research and Development strategy adjustment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=7 | Terminated | Sponsor: Chimagen Biosciences, Ltd | N=165 ➔ 7 | Recruiting ➔ Terminated; Sponsor's Research and Development strategy adjustment

Enrollment change • Trial termination • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD19

Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov) - P1 | N=209 | Recruiting | Sponsor: BioRay Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Phase classification: P1/2 ➔ P1

Enrollment open • Phase classification • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline (GSK Press Release) - "GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen)....today announced an agreement for GSK to acquire CMG1A46...from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases....Under the terms of this agreement, GSK will pay $300 million upfront to acquire full global rights to CMG1A46. In addition, Chimagen will be eligible to receive success-based development and commercial milestone payments for CMG1A46 totalling $550 million....GSK aims to begin a phase I trial in lupus in 2025."

Licensing / partnership • New P1 trial • Lupus Nephritis • Systemic Lupus Erythematosus

A Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov) - P1/2 | N=209 | Not yet recruiting | Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=165 | Recruiting | Sponsor: Chimagen Biosciences, Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2022 ➔ Jul 2022

Enrollment open • Trial initiation date • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD19

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=165 | Not yet recruiting | Sponsor: Chimagen Biosciences, Ltd

New P1/2 trial • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD19